US · Healthcare · Medical Devices
EPS came in at 0.89 against a street estimate of 0.81 — a beat of 9.9%.
Analysts rate Enovis Corp a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $41.58.
| Fund | Stake |
|---|---|
| BlackRock Inc | 17.26% |
| American Century Companies Inc | 8.28% |
| Vanguard Portfolio Management, LLC | 6.62% |
| Vanguard Capital Management, LLC | 4.43% |
| Dimensional Fund Advisors, Inc. | 4.42% |
| Rubric Capital Management LP | 4.26% |
| State Street Corp | 4.17% |
| Davenport & Company LLC | 4.07% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-05-19 |
| Quarterly report · Q2 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-06 |
| Annual report FY2025 | 2026-02-26 |
| Results announced · Q1 2026 | 2026-02-26 |
| Reg FD disclosure · Q1 2026 | 2026-01-12 |
| Quarterly report · Q4 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Enovis Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.